Efficacy and safety of twice‐daily tramadol hydrochloride bilayer sustained‐release tablets with an immediate release component for postherpetic neuralgia: Results of a Phase III, randomized, double‐blind, placebo‐controlled, treatment‐withdrawal study
Background: We investigated the efficacy and safety of twice‐daily bilayer sustained‐release tramadol hydrochloride tablets (35% immediate‐release; 65% sustained‐release) in patients with postherpetic neuralgia. Methods: This was a Phase III treatment‐withdrawal study with 1–4‐week dose‐escalation,...
| Publicado en: | Pain Practice Vol. 23; no. 3; pp. 277 - 290 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | research tables/charts randomized controlled trial Journal Article |
| Publicado: |
Wiley-Blackwell
Mar2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |